Rhythm Biosciences (ASX:RHY) has reached a pivotal commercial milestone by executing a multi-year supply agreement with US-based Quansys Biosciences.
The deal appoints Quansys as the primary contract manufacturer for ColoSTAT, Rhythm’s blood-based diagnostic test designed for the early detection of colorectal cancer.
The partnership transitions the relationship from a two-year development phase into full-scale commercial production.
Under the agreement, Quansys will utilise its ISO13485-certified facilities to produce consumable reagent kits, providing the scalable capacity necessary to support the upcoming ColoSTAT Access Program and subsequent global rollout.
The contract includes a fixed pricing framework for the first two years, offering Rhythm significant predictability regarding cost of goods and reducing operational risks associated with manufacturing scale-up.
CEO Dr. David Atkins highlighted that securing a partner with proven expertise in multiplex immunoassays ensures a quality-assured supply chain as the company prepares for broader market entry.
Quansys CEO Adam Brown added that the collaboration aligns with their mission to empower clinicians with transformative diagnostic tools.
At the time of reporting, Rhythm Biosciences’ share price was $0.19.